Changed number of shares in iZafe Group AB

Stockholm, Sweden. iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – a leading life science company in the digitalization of medication management decided in November 2018 on a warrant program, TO 6 B. The exercise period for the warrants of series TO 6 B took place during the period 14 May 2021 to 28 May 2021 and has thus been completed. A total of 7,974 TO 6 B was used for subscription, implying a utilization rate of approximately two percent.

A total of 7,974 warrants were used, corresponding to approximately two percent of all issued warrants, for subscription of 7,974 Class B shares at a subscription price of SEK 2.60 per Class B share. Through the exercised warrants, iZafe Group will thus receive just over SEK 20 thousand before issue costs.

Number of shares and share capital
Through the exercise of the warrants, the number of shares in iZafe Group will increase by 7,974 Class B shares, from 34,827,700 to 34,835,674 Class B shares. The share capital thereby increases by SEK 7,974, from SEK 35,427,700 to SEK 35,435,674.

The issue entails a dilution effect of the share capital of approximately 0.02 percent.

Webbdesign av Comlog Webbyrå Stockholm